Over 100 crore Covishield doses have been given in India and abroad which is a testimony of its safety and efficacy, Serum Institute has informed the DCGI which had sought more data for granting full marketing approval to the Covid vaccine, official sources said on Tuesday.
Covishield is currently authorized for emergency use in the country. Serum Institute of India (SII), on October 25, had applied to the Drugs Controller General of India (DCGI) seeking regular market authorization for the vaccine.
The drug regulator in December sought more data and documents for it. Following this, Prakash Kumar Singh, the Director, Government and Regulatory Affairs at SII, recently submitted a response along with more data and information.
In addition to the successful completion of phase 2/3 clinical study in India, till now, more than 100 crore doses of Covishield vaccine have been administered to the people in this country and worldwide, Singh is learnt to have stated in the response.
Such a large-scale vaccination with Covishield and containment of COVID-19 infection is in itself a testimony of the safety and efficacy of the vaccine, he said.
"It is a matter of pride for us that we have been a part of the world's largest vaccination drive under the dynamic and visionary leadership of our Prime Minister Narendra Modi.
"Under the kind guidance of Union Health Minister Mansukh Mandaviya, Team Government of India and leadership of our CEO Adar C Poonawalla, Team SII has been working relentlessly to manufacture and supply Covishield for making the world's largest COVID-19 vaccination drive successful," Singh is learnt to have stated in the reply.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU